CN1267110C - Elsholizia extract prepn and its quality control method and new use - Google Patents
Elsholizia extract prepn and its quality control method and new use Download PDFInfo
- Publication number
- CN1267110C CN1267110C CN 02153995 CN02153995A CN1267110C CN 1267110 C CN1267110 C CN 1267110C CN 02153995 CN02153995 CN 02153995 CN 02153995 A CN02153995 A CN 02153995A CN 1267110 C CN1267110 C CN 1267110C
- Authority
- CN
- China
- Prior art keywords
- oil
- mola
- preparation
- cell
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000003908 quality control method Methods 0.000 title abstract description 9
- 239000000284 extract Substances 0.000 title description 6
- 238000002360 preparation method Methods 0.000 claims abstract description 23
- 239000000341 volatile oil Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims description 31
- 241000702670 Rotavirus Species 0.000 claims description 10
- 230000000741 diarrhetic effect Effects 0.000 claims description 5
- 241000700605 Viruses Species 0.000 abstract description 16
- 206010012735 Diarrhoea Diseases 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 5
- 210000002784 stomach Anatomy 0.000 abstract description 2
- 241000894006 Bacteria Species 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000000936 intestine Anatomy 0.000 abstract 1
- 239000003921 oil Substances 0.000 description 48
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 46
- 241000357437 Mola Species 0.000 description 45
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 36
- 210000004027 cell Anatomy 0.000 description 24
- 239000005844 Thymol Substances 0.000 description 23
- 229960000790 thymol Drugs 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 239000013558 reference substance Substances 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- HHTWOMMSBMNRKP-UHFFFAOYSA-N carvacrol Natural products CC(=C)C1=CC=C(C)C(O)=C1 HHTWOMMSBMNRKP-UHFFFAOYSA-N 0.000 description 15
- RECUKUPTGUEGMW-UHFFFAOYSA-N carvacrol Chemical compound CC(C)C1=CC=C(C)C(O)=C1 RECUKUPTGUEGMW-UHFFFAOYSA-N 0.000 description 15
- 235000007746 carvacrol Nutrition 0.000 description 15
- WYXXLXHHWYNKJF-UHFFFAOYSA-N isocarvacrol Natural products CC(C)C1=CC=C(O)C(C)=C1 WYXXLXHHWYNKJF-UHFFFAOYSA-N 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 238000000034 method Methods 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000008838 gegenqinlian Substances 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000006187 pill Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000008107 starch Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000012362 glacial acetic acid Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 238000011003 system suitability test Methods 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010019160 Pancreatin Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000002147 killing effect Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 229940055695 pancreatin Drugs 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- 210000003501 vero cell Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 2
- 206010051511 Viral diarrhoea Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000013553 cell monolayer Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- -1 suspensoid Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000212384 Bifora Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 206010012742 Diarrhoea infectious Diseases 0.000 description 1
- 206010014025 Ear swelling Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000009711 Huoxiang-zhengqi Substances 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019082 Osmanthus Nutrition 0.000 description 1
- 241000333181 Osmanthus Species 0.000 description 1
- 239000005662 Paraffin oil Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000422846 Sequoiadendron giganteum Species 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 208000012873 acute gastroenteritis Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000001142 anti-diarrhea Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical compound [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- ALWKGYPQUAPLQC-UHFFFAOYSA-N neostigmine Chemical compound CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 ALWKGYPQUAPLQC-UHFFFAOYSA-N 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 230000000283 vasomotion Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 229940100050 virazole Drugs 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention discloses a preparation of herba elsholtziae volatile oil, a quality control method, and a new purpose thereof. The preparation of herba elsholtziae volatile oil has the functions of resisting viruses, resisting bacteria, resisting inflammatory, stopping diarrhea, alleviating pain and removing heat, and can suppress stomach intestine hyperfunction.
Description
Technical field
The preparation, method of quality control that the present invention relates to a kind of Chinese medicine extract with and new purposes, particularly relate to a kind of preparation, method of quality control and new purposes of Herba Moslae extract.
Background technology
Diarrhoea (infectious, non-infectious) sickness rate height, also higher in the certain areas case fatality rate, be transworld serious problems.The traditional Chinese medical science is to the then determination of treatment based on pathogenesis obtained through differentiation of symptoms and signs of carrying out of diarrheal treatment more, cold-damp syndrome person huoxiang zhengqi powder master it, damp-heat syndrome person GEGEN QINLIAN TANG master it, dyspepsia card person lenitive pill master it, stagnation of liver-QI takes advantage of spleen person's tongxieyao formula master it, weakness of the spleen and stomach person SHENLING BAISHU SAN master it, kidney yang deficiency card person SISHEN WAN master it.So also there is the soil single-prescription of employing that gastroenteritis is carried out the treatment according to differentiation of diseases person.In the last few years, the report of Chinese traditional treatment viral diarrhea was many, but it is less to form the new drug person.The characteristics of Chinese medicine are to be good at recuperating gastrointestinal tract function, few side effects, but the action intensity of pathogen slightly is inferior to Western medicine.How modern medicine treats with the physical exercise therapy of antimicrobial drug fluid,matching infectious diarrhea, has obviously improved curative effect.The research of nearly microbial ecological agent has during the last ten years caused scholar's attention with application, has carried out vaccine research simultaneously, but owing to cause that the diarrheal pathogen is a lot, lacks cross immunity each other, so the development of vaccine is made slow progress always.Along with going deep into of research, also more and more clearer to the toxic and side effects of antimicrobial drug, as toxicity and gastrointestinal reaction, anaphylaxis and superinfection etc. to kidney, liver, neural spirit, blood.At present viral diarrhea is still lacked specific medicine, the report that external useful lactobacillus, interferon, virazole etc. are treated, domestic useful viral infection chicken, the preparation antibody preparation carries out therapist from ovum gallinaceum then, but still among research and development.In recent years developed the rotavirus live vaccine, among applying.According to the data of WHO, it is inferior that the whole world annual diarrhoea case can reach 30-50 hundred million examples, has 500-1000 ten thousand cases dead because of serious diarrhoea approximately.Inferior, non-, draw the area below 5 years old among the child, annual diarrhoea person is taken place more than 1,000,000,000 person-times, the dead about 5,000,000.According to reports, China suffers from diarrhoea for annual about 8.36 hundred million person-times, and wherein child below 5 years old accounts for 2.09 hundred million person-times, accounts for 1/4.According to Ministry of Public Health in 1993 report, China's acute gastroenteritis two all prevalences are that 11.74%, two all acute diseases constitute by the disease kind and account for 8.36%, come after acute nasopharyngitis and the influenza, occupy ill the 3rd of two weeks of the resident of urban and urual areas of whole country.Rotavirus is to be found by Bishop etc. in 1973.1.4 hundred million person-times of rotavirus diarrhea can take place every year in whole world child below 5 years old, and death can reach 1,000,000 people.Rotavirus is the important cause of disease of infantile diarrhea, has found to cause the one-tenth Human reoviruslike agent of adult diarrhea afterwards again.
Summary of the invention
The object of the invention is to provide a kind of treatment diarrheal Herba Moslae extract preparation.
The object of the invention also is to provide the method for quality control of Herba Moslae and extract thereof.
The object of the invention also is to provide the new pharmaceutical use of Herba Moslae and extract thereof.
The present invention seeks to be achieved through the following technical solutions:
The preparation of Herba Moslae volatile oil: the Herba Moslae herb, cutting adds 6-10 times of water gaging, and vapor distillation extracted 4-8 hour, isolated the volatilization oil reservoir, promptly.
Pharmaceutical preparation of the present invention contains the Herba Moslae volatile oil of 1%-99% and the excipient of 99%-1% (medicine that comprises other adapted), preferably contain the Herba Moslae volatile oil of 30%-80% and the pharmaceutical excipient of 70%-20% (comprising the medicine that other compatibility is used), preferably contain the Herba Moslae volatile oil of 60%-70% and the excipient of 40%-30% (comprising the medicine that other compatibility is used).
Press practice of pharmacy, Herba Moslae volatile oil of the present invention can be prepared into the various clinical pharmaceutical dosage form, comprise the dosage form of oral formulations or parenterai administration.Said oral formulations is selected from any in tablet, capsule, pill, granule, suspensoid, drop pill, the oral liquid; Said parenterai administration dosage form is selected from a kind of in the middle of injection, aerosol, suppository or the subcutaneous administration dosage form.
Adjuvant in the medicine of the present invention is meant conventional excipient, as solvent, disintegrating agent, correctives, antiseptic, coloring agent, binding agent etc.The medicine that other compatibility in the medicine of the present invention is used, the MOLA oil that refers to effective dose is certain medicine material, again compatibility other allowed the Chinese medicine or the chemical drugs that share.
Above-mentioned volatile oil (MOLA oil) is yellowish supernatant liquid; Special aroma is arranged, acrid in the mouth; Store with the passing of time, color deepens slightly.
Contain following discriminating and/or content assaying method in the method for quality control of MOLA oil:
Differentiate: by the MOLA oil content assaying method, high-efficient liquid phase chromatogram has corresponding absworption peak in the retention time identical with the carvacrol reference substance with thymol.
Assay: measure according to high performance liquid chromatography (2000 editions appendix VID of Chinese Pharmacopoeia).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; 50-70: 50-30: 1-3 methanol-water-glacial acetic acid is a mobile phase; The detection wavelength is 276nm.Number of theoretical plate calculates by the thymol peak should be not less than 10000, calculates by the carvacrol peak and should be not less than 15000.The preparation of reference substance solution, precision take by weighing thymol reference substance 8mg and thymol reference substance 4mg, put in the 100ml measuring bottle, add methanol to scale, shake up, and, contain thymol 80 μ g among every ml that is, contain carvacrol 40 μ g.The about 0.017g of this product is got in the preparation of need testing solution, and accurate the title decides, and puts in the 10ml measuring bottle, adds methanol to scale, shakes up, and precision is measured 0.9ml, to the 10ml measuring bottle, adds methanol and is diluted to scale, shakes up, promptly.Algoscopy, accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing inject chromatograph of liquid, measure, promptly.This product contains carvacrol (C
10H
14O) and thymol (C
10H
14O) total amount must not be less than 55%.
Differentiate: by the MOLA oil content assaying method, high-efficient liquid phase chromatogram has corresponding absworption peak in the retention time identical with the carvacrol reference substance with thymol.
Contain following content assaying method in the method for quality control of Herba Moslae of the present invention:
Assay: precision takes by weighing the about 0.2g of Herba Moslae fine powder, puts in the 100ml tool plug conical flask, accurate methanol 20ml, the close plug of adding, claim decide weight, supersound process 20-30 minute, put coldly, weight decided in title again, supply the weight that subtracts mistake with methanol, shake up, filter, get subsequent filtrate as need testing solution.Measure according to high performance liquid chromatography (2000 editions appendix VID of Chinese Pharmacopoeia).Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; 50-70: 50-30: 1-3 methanol-water-glacial acetic acid is a mobile phase; The detection wavelength is 276nm.Number of theoretical plate calculates by the thymol peak should be not less than 10000, calculates by the carvacrol peak and should be not less than 15000.The preparation of reference substance solution, precision take by weighing thymol reference substance 8mg and thymol reference substance 4mg, put in the 100ml measuring bottle, add methanol to scale, shake up, and, contain thymol 80 μ g among every ml that is, contain carvacrol 40 μ g.Algoscopy, accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing inject chromatograph of liquid, measure, promptly.Herba Moslae contains carvacrol (C
10H
14O) and thymol (C
10H
14O) total amount must not be less than 0.80%.
The pharmacodynamic study result of Herba Moslae of the present invention and volatile oil thereof shows that MOLA oil has following function:
1. the antivirus action of MOLA oil: 12.5～25nl/ml MOLA oil can suppress children's's rotavirus RDTA-I type (Wa strain) growth and breeding on African green monkey kidney cell.
2. the antibacterium of MOLA oil effect: MOLA oil can reduce Salmonella enteritidis abdominal cavity infection mortality of mice (P＜0.05); Can reduce the content (P＜0.05～0.01) of pathogenic bacterium in the mice stool of Salmonella enteritidis peroral infection; External, to common pathogens such as Escherichia coli, Shiga bacillus, proteus vulgaris, staphylococcus aureus, staphylococcus epidermidiss, stronger inhibition growth effect is arranged, and test is with in the 44 strain bacterial strains, and minimum inhibitory concentration≤1ul oil/ml accounts for 79.5%.
3. the anti-diarrhea effect of MOLA oil: loose stool rate, diarrhea rate, diarrhoea index and the diarrhoea degree (P＜0.05～0.001) that reduce the diarrhoea model mice due to the 100% Folium Sennae decoct significantly.
4. MOLA oil is to the influence of gastrointestinal function: this medicine can reduce hyperfunction mouse small intestine propulsion functions (P＜0.05～0.001) due to normal and the neostigmine, prolong defecation time, reduce defecation quantity (P＜0.05～0.001), slow down gastric emptying motion (P＜0.01～0.001), intestinal smooth muscle excitement due to the reduction stomachial secretion function (P＜0.001), stripped intestinal smooth muscle spontaneous vasomotion of inhibition normal guinea pig and acetylcholine.
5. the analgesic effect of MOLA oil: MOLA oil reduces very significantly by the mouse writhing number due to 0.7% acetic acid (all P＜0.001), and suppression ratio reaches 51.3～55.7%.
6. the antiinflammatory action of MOLA oil: MOLA oil suppresses significantly by dimethylbenzene induced mice ear swelling (P＜0.01～0.001), suppress the vascular permeability (P＜0.05～0.001) that histamine causes significantly, suppress abdominal cavity leukoplania (P＜0.05～0.001) due to the sodium carboxymethyl cellulose.
7. the antipyretic effect of MOLA oil: MOLA oil saccharomycetic rat temperature is raise and endotoxin due to the rabbit body temperature rising inhibitory action (P＜0.05～0.001) is significantly all arranged.
Following experimental example is used to further specify the present invention.
Experimental example:MOLA oil suppresses the effect of children's's rotavirus ROTA-I type (Wa strain)
Materials and methods:
1. medicine: tried the thing MOLA oil, faint yellow, proportion 0.95726g/ml, 16mg oil/1g crude drug, lot number: 20000601, Beijing big tree institute of Pharmaceutical Research provides.Getting the 0.5ml MOLA oil adds the 0.5ml tween 80 (Shanghai the 18 pharmaceutical factory produces, lot number: add the dilution of 4ml growth-promoting media after 960520) being mixed.It is standby to put 4 ℃ of refrigerators.
Contrast medicine GEGEN QINLIAN DIWAN, the Liuzhou city pharmaceutical factory of traditional Chinese medicine produces, and accurate word (1991) is defended No. 017004 in osmanthus, lot number: 990721.Get 10 milliliters of dissolvings of 1g medicine adding distil water, 2000 rev/mins, centrifugal 10 minutes, get the supernatant water-bath and boil sterilization in 10 minutes, put 40 ℃ of refrigerators and preserve.
The above-mentioned medicinal preceding pH=7.2 that transfers
2. cell: African green monkey kidney (Vero) passage cell, the cell that grows up to monolayer is individual cells through the digestion of trypsinization liquid, is made into 60,000 cell/ml with growth-promoting media, inserts the cell pipe, the 1ml/ pipe.
3. viral: children's's rotavirus ROTA-1 type (Wa strain) is provided TCID by Virology Inst., China Academy of Preventive Medicine Sciences
5010
-7, during test with 100 TCID
500.1ml.Before the Wa strain is used, add 370 ℃ of water-baths of 0.05ml pancreatin (200ug/ml) 30 minutes with 1ml virus liquid.
4. reagent: Eagles MEM dry powder, U.S. GIBCO product.Hyclone, the Tianjin Blood Research Institute is produced; Lot number: 9925, L-glutaminate, Sigma import packing, lot number: 911015.Penicillin, streptomycin.
The reagent preparation:
Growth-promoting media: Eagles adds 1% mycillin, 1% glutamine, 10% calf serum, with preceding accent PH=7.4.
Keep liquid: Eagles adds 1% mycillin, 1% glutamine, and 200ug/ml pancreatin (final concentration is 2ug/ml) is with preceding accent PH=7.4.
Cell dissociation buffer: 0.25% pancreatin, with no calcium magnesium phosphate buffer preparation.
5. test articles for use and instrument:
Culture bottle, test tube, measuring pipette, incubator, refrigerator, baking box, water bath, low temperature refrigerator, liquid nitrogen container etc. are homemade.
6. test method:
(1) MOLA oil, GEGEN QINLIAN DIWAN and tween 80 are to the toxic action of Vero cell: will dilute good medicine, tween 80 inserts and grows up in the test tube of cell monolayer, puts 37 ℃ of incubators and cultivates, every day, observation of cell changed.
(2) medicine is to the direct killing effect of virus: put 37 ℃ of incubators 1 hour after will diluting good medicine and viral mixed in equal amounts.Access grows up in the test tube of cell monolayer then, and every pipe 0.2ml is put 37 ℃ of absorption 1 hour.Keep liquid 1ml with keeping to add after liquid is washed twice.Put 37 ℃ of incubators and cultivate, observation of cell pathological changes every day (CPE), when virus control occurs ++ ++ the time, termination test.
(3) medicine inhibitory action that virus is bred in cell: the virus that will handle inserts in the cell pipe, every pipe 0.1ml is put 37 ℃ of absorption 1 hour, with keep liquid wash after twice add respectively contain different pharmaceutical concentration keep liquid 1ml, put 37 ℃ of cultivations, every day the observation of cell pathological changes, when the virus control pipe occurs ++ ++ the time, termination test.
Annotate: cytopathy :+25%, ++ 50%, +++75%, ++ ++ 100%.
More than medicine contrast, virus control, cell contrast are established in test simultaneously, and every test group 4 solencytes repeat to do experiment twice.
The result:
1. MOLA oil the results are shown in Table 1 to the toxicity test of Vero cell.
Table 1 MOLA oil is to the toxicity test result of Vero cell
| Group | Drug level/ml | Cell pipe number | Cytotoxicity pipe number |
| MOLA oil | 100nl 50nl 25nl 12.5nl | 4 4 4 4 | 4 0 0 0 |
| GEGEN QINLIAN DIWAN | 5mg 2.5mg 1.25mg | 4 4 4 | 4 0 0 |
| Tween 80 | 200nl 100nl | 4 4 | 2 0 |
| The Vero contrast | 4 | 0 |
4 concentration MOLA oil are inserted the cell pipe respectively, and final concentration is 100,50,25,12.5nl/ml.Each concentration 4 pipe was observed 7 days.Pair cell was toxic when MOLA oil concentration was 100nl/ml as a result, and concentration is 50,25, and pair cell does not have toxicity during 12.5nl/ml; Pair cell is toxic during GEGEN QINLIAN DIWAN 5mg/ml, and pair cell does not have toxicity when 2.5mg/ml and 1.25mg/ml; Pair cell does not have toxicity during tween 80 100nl/ml.
2. MOLA oil is to the direct killing effect result of the test of virus: the results are shown in Table 2.
Table 2 MOLA oil is to the direct killing effect result of the test of virus
| Group | Drug level/ml | The inoculated tube number | Positive pipe number | The negative tube number |
| The MOLA oil group | 50nl 25nl | 8 8 | 8 8 | 0 0 |
| The GEGEN QINLIAN DIWAN group | 10mg 5mg | 8 8 | 8 8 | 0 0 |
| The tween 80 group | 100nl 50nl | 8 8 | 8 8 | 0 0 |
| Wa strain cellular control unit matched group | 8 8 | 8 0 | 0 8 |
It is as shown in the table: each administration group of MOLA oil does not have direct deactivation to children's's rotavirus ROTA-1 type.
MOLA oil to virus in intracellular breeding inhibitory action result of the test: the results are shown in Table 3.
Table 3: MOLA oil to virus in intracellular breeding inhibitory action result of the test:
| Group | Drug level/ml | The pipe number | Positive pipe | Negative tube |
| The MOLA oil group | 25nl 12.5nl 6.25nl 3.12nl | 8 8 8 8 | 0 0 2 8 | 8 8 6 0 |
| The GEGEN QINLIAN DIWAN group | 2.5mg 1.25mg | 8 8 | 8 8 | 0 0 |
| The tween 80 group | 100nl 50nl | 8 8 | 8 8 | 0 0 |
| The contrast of Wa strain control cells | 8 8 | 8 0 | 0 8 |
It is as shown in the table, when MOLA oil concentration is 25nl/ml, 12.5nl/ml, can suppress virus fully in intracellular breeding, when concentration is 6.25nl/ml, virus is bred certain inhibitory action in cell, when concentration is 3.1nl/ml virus being bred in cell does not have inhibitory action.GEGEN QINLIAN DIWAN, each concentration group of tween 80 is bred in cell virus does not have inhibitory action.
Embodiment 1:Herba Moslae quality control:
Precision takes by weighing the about 0.2g of Herba Moslae fine powder, puts in the 100ml tool plug conical flask, accurate methanol 20ml, the close plug of adding, claim decide weight, supersound process 30 minutes is put coldly, and weight decided in title again, supply the weight that subtracts mistake with methanol, shake up, filter, get subsequent filtrate as need testing solution.Measure according to high performance liquid chromatography (2000 editions appendix VID of Chinese Pharmacopoeia).Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; 60: 40: 2 methanol-water-glacial acetic acid are mobile phase; The detection wavelength is 276nm.Number of theoretical plate calculates by the thymol peak should be not less than 10000, calculates by the carvacrol peak and should be not less than 15000.The preparation precision of reference substance solution takes by weighing thymol reference substance 8mg and thymol reference substance 4mg, puts in the 100ml measuring bottle, adds methanol to scale, shakes up, and, contains thymol 80 μ g among every ml that is, contains carvacrol 40 μ g.Algoscopy, accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing inject chromatograph of liquid, measure, that is and, Herba Moslae contains carvacrol (C
10H
14O) and thymol (C
10H
14O) total amount must not be less than 0.80%.
Embodiment 2:The method of quality control of MOLA oil
Assay: measure according to high performance liquid chromatography (2000 editions appendix VID of Chinese Pharmacopoeia).
Chromatographic condition and system suitability test are filler with octadecylsilane chemically bonded silica; 60: 40: 2 methanol-water-glacial acetic acid are mobile phase; The detection wavelength is 276nm.Number of theoretical plate calculates by the thymol peak should be not less than 10000, calculates by the carvacrol peak and should be not less than 15000.The preparation precision of reference substance solution takes by weighing thymol reference substance 8mg and thymol reference substance 4mg, puts in the 100ml measuring bottle, adds methanol to scale, shakes up, and, contains thymol 80 μ g among every ml that is, contains carvacrol 40 μ g.The about 0.017g of this product is got in the preparation of need testing solution, and accurate the title decides, and puts in the 10ml measuring bottle, adds methanol to scale, shakes up, and precision is measured 0.9ml, to the 10ml measuring bottle, adds methanol and is diluted to scale, shakes up, promptly.Algoscopy, accurate respectively reference substance solution and each 20 μ l of need testing solution of drawing inject chromatograph of liquid, measure, that is and, this product contains carvacrol (C
10H
14O) and thymol (C
10H
14O) total amount must not be less than 55%.
Differentiate: by the MOLA oil content assaying method, high-efficient liquid phase chromatogram has corresponding absworption peak in the retention time identical with the carvacrol reference substance with thymol.
Embodiment 3:Capsular preparation
MOLA oil 250 grams, starch 2500 grams carry out drying earlier with starch, cross 120 mesh sieves, then with the MOLA oil mix homogeneously, cross twice 120 mesh sieves, and fully mixing is made 1000 capsules altogether, and every intragranular contains 250 milligrams of MOLA oil.Oral, every day 2-3 time, each 1-2 grain.
Embodiment 4:The preparation of drop pill
Take by weighing the 300g Macrogol 4000, in water-bath, melt, add MOLA oil raw material 100g, stir, in the impouring insulating tube, regulate thermostat, make medicinal liquid under 80-90 ℃, splash in the liquid paraffin that cooled off (temperature ± 4 ℃), after dripping off, to blot paraffin oil on the pill impouring filter paper, add a small amount of Pulvis Talci again, mixing gets 1000 of MOLA oil drop pill.Oral, a 2-3 grain, three times on the one, one after each meal.
Embodiment 5:The preparation of capsule
Herba Moslae 1000g, medical starch 1000g, mix homogeneously, the 0# capsule of packing into, every 0.35g, treatment diarrhoea, each oral 1-2 grain, twice of every day.
Embodiment 6:The preparation of tablet
MOLA oil raw material 1000g, medical starch 500g, mix homogeneously is used an amount of alcohol granulation, through the pelletizing machine granulate, tabletting, every 0.25g, oral, each 1-2 sheet, twice of every day.
Embodiment 7:The preparation of granule
MOLA oil raw material 100g, starch 1000g, Icing Sugar 400g, mix homogeneously is used an amount of alcohol granulation, and drying, granulate, packing are promptly.Oral, a 5g, twice on the one.
Embodiment 8:The preparation of injection
MOLA oil 10g, propylene glycol 20ml, Polyethylene Glycol-40050ml, water for injection 300ml mixes heating in water bath 30 minutes, add benzyl alcohol 50ml, reuse water for injection adds to 1000ml, handles 10 minutes in ultrasound wave, heats 30 minutes in the water-bath again, transfer pH value 5.5-6.5, filter clear and bright, embedding, the sterilization promptly.Every 2ml, intramuscular injection, a 2ml, 1-2 time on the one.
Claims (2)
1, the application of Herba Moslae in diarrheal medicine due to the preparation treatment rotavirus.
2, the application of Herba Moslae volatile oil in diarrheal medicine due to the preparation treatment rotavirus.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153995 CN1267110C (en) | 2002-12-09 | 2002-12-09 | Elsholizia extract prepn and its quality control method and new use |
| CNB2005100049926A CN100428925C (en) | 2002-12-09 | 2002-12-09 | Preparation of Herba Moslae extract and quality control thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02153995 CN1267110C (en) | 2002-12-09 | 2002-12-09 | Elsholizia extract prepn and its quality control method and new use |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100049926A Division CN100428925C (en) | 2002-12-09 | 2002-12-09 | Preparation of Herba Moslae extract and quality control thereof |
| CNB2005100049930A Division CN100347539C (en) | 2002-12-09 | 2002-12-09 | Herba Moslae quality control |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1506093A CN1506093A (en) | 2004-06-23 |
| CN1267110C true CN1267110C (en) | 2006-08-02 |
Family
ID=34235399
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100049926A Expired - Fee Related CN100428925C (en) | 2002-12-09 | 2002-12-09 | Preparation of Herba Moslae extract and quality control thereof |
| CN 02153995 Expired - Fee Related CN1267110C (en) | 2002-12-09 | 2002-12-09 | Elsholizia extract prepn and its quality control method and new use |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100049926A Expired - Fee Related CN100428925C (en) | 2002-12-09 | 2002-12-09 | Preparation of Herba Moslae extract and quality control thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN100428925C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100418514C (en) * | 2006-06-05 | 2008-09-17 | 谢华 | Soft capsule with elslholtzia and method for preparing same |
| CN102451228A (en) * | 2010-10-26 | 2012-05-16 | 中国医学科学院药用植物研究所 | Preparation method and application of antibacterial and antiviral elsholtzia densa benth volatile oil |
| CN109419846B (en) * | 2017-08-31 | 2021-07-16 | 安徽天康(集团)股份有限公司 | Application of herba Moslae volatile oil in treating norovirus infectious diarrhea |
| CN107843676A (en) * | 2017-11-15 | 2018-03-27 | 广州美瑞泰科生物工程技术有限公司 | The detection method of carvacrol and Thymol in a kind of plant extract feed additive |
| CN111135223B (en) * | 2020-02-13 | 2022-02-22 | 湖南省中医药研究院 | Application of flavored herba Moslae oral liquid in preparation of medicine for treating infantile rotavirus enteritis complicated with myocardial injury |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1282598A (en) * | 1999-07-28 | 2001-02-07 | 向守永 | Particles of antidiarrheal Xiangzhu decoction |
-
2002
- 2002-12-09 CN CNB2005100049926A patent/CN100428925C/en not_active Expired - Fee Related
- 2002-12-09 CN CN 02153995 patent/CN1267110C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN100428925C (en) | 2008-10-29 |
| CN1506093A (en) | 2004-06-23 |
| CN1679707A (en) | 2005-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112472698B (en) | Application of bromophenol-pyrazoline compounds in treatment of porcine coronavirus diseases | |
| CN101850008A (en) | Bacillus Ling oral liquid and preparation method thereof | |
| CN102274314A (en) | Evergreen coccidian powder and preparation method thereof | |
| CN101869611A (en) | Admixture capable of repelling chicken coccidiosis and stopping dysentery and preparation method thereof | |
| CN103341114A (en) | Application of amomum tsao-ko oil in preparation of drugs for treating bacterial infectious diseases | |
| CN101596246B (en) | Smoked plum extractive and wild jujube seed extractive compound preparation as well as preparation method and application thereof | |
| CN101032547A (en) | Anti-inflammatory and antivirotic medicine composition | |
| CN1682842A (en) | Chinese medicine composition for diminishing-inflammation and detoxication and its preparing method and use | |
| CN1267110C (en) | Elsholizia extract prepn and its quality control method and new use | |
| CN1686185A (en) | Traditional Chinese medicina preparation for treating oral cavity, throat disease and its preparation method | |
| CN1680355A (en) | Preparation of suaveolic flavone for treating chronic pharyngitis and chronic tonsilltiis | |
| CN1283274C (en) | Elsholizia extract capsule for treating diarrhea and its prepn | |
| CN101698011B (en) | Medicine for treating epidemic diarrhea of livestock and poultry | |
| CN102188494B (en) | Medicament for treating high fever of pigs with pure Chinese medicine | |
| CN1269498C (en) | Chinese medicinal composition possessing antipyretic and its preparation method and quality control method | |
| CN100347539C (en) | Herba Moslae quality control | |
| CN1248701C (en) | Elsholizia extract granule for treating diarrhea and its prepn | |
| CN103520316B (en) | Traditional Chinese medicine for preventing and treating livestock and poultry diarrhoea and preparation method | |
| CN1876045A (en) | A Chinese medicinal composition, its preparation process and quality control method | |
| CN1686423A (en) | Medicinal composition containing scutellaria glucoside and bupleurum and its preparation method | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN1814188A (en) | Vitaminc lonicera and forsythia capsule and preparing method | |
| CN1947750A (en) | Traditional Chinese medicine for treating newcastle disease | |
| CN104491011B (en) | A kind of rotavirus for the treatment of causes Chinese medicine composition of baby diarrhea and preparation method thereof | |
| CN1879736A (en) | Antibacterial Chinese medicinal composition for birds and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: SHANDONG NEW AGE PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: ZHANG RUIXIANG Effective date: 20100426 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 100028 NO.7, 2/F, BUILDING 57, XIBAHE DONGLI, CHAOYANG DISTRICT, BEIJING CITY TO: 273400 NO.1, NORTH OUTER RING ROAD, FEI COUNTY, SHANDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100426 Address after: 273400 Shandong province Feixian County North Ring Road No. 1 Patentee after: Shandong Xinshidai Pharmaceutical Industry Co., Ltd. Address before: 100028 Beijing Chaoyang District City 57 east 2 floor No. 7 Patentee before: Zhang Ruixiang |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060802 Termination date: 20191209 |